Publicacions en què col·labora amb Nuria Soldevila (12)

2022

  1. Effect of COVID-19 Pandemic on Invasive Pneumococcal Disease in Children, Catalonia, Spain

    Emerging Infectious Diseases, Vol. 28, Núm. 11, pp. 2321-2325

2021

  1. Necrotizing pneumonia due to Streptococcus pneumoniae in children during the period of non-systematic use of PCV13 in Catalonia, Spain

    Enfermedades Infecciosas y Microbiologia Clinica, Vol. 39, Núm. 10, pp. 486-492

2020

  1. Erratum for Hernández et al., "Invasive Pneumococcal Disease and Influenza Activity in a Pediatric Population: Impact of PCV13 Vaccination in Epidemic and Nonepidemic Influenza Periods"

    Journal of clinical microbiology

2019

  1. Complicated pneumococcal pneumonia with pleural effusion or empyema in the 13-valent pneumococcal conjugate vaccine era

    Pediatric Pulmonology, Vol. 54, Núm. 5, pp. 517-524

  2. Invasive pneumococcal disease and influenza activity in a pediatric population: Impact of PCV13 vaccination in pandemic and nonpandemic influenza periods

    Journal of Clinical Microbiology, Vol. 57, Núm. 8

2017

  1. Effectiveness of the 13-valent pneumococcal conjugate vaccine in preventing invasive pneumococcal disease in children aged 7-59 months. A matched case-control study

    PLoS ONE, Vol. 12, Núm. 8

2015

  1. Effectiveness of non-pharmaceutical measures in preventing pediatric influenza: A case-control study

    BMC Public Health, Vol. 15, Núm. 1

2013

  1. Are risk factors associated with invasive pneumococcal disease according to different serotypes?

    Human Vaccines and Immunotherapeutics

  2. Clinical features of influenza disease in admitted children during the first postpandemic season and risk factors for hospitalization: A multicentre Spanish experience

    Clinical Microbiology and Infection, Vol. 19, Núm. 3

  3. Risk factors for invasive pneumococcal disease in a community with a high proportion of non vaccine serotypes

    Vaccine, Vol. 31, Núm. 6, pp. 960-966

2012

  1. 2009 H1N1: Risk factors for hospitalization in a matched case-control study

    European Journal of Pediatrics, Vol. 171, Núm. 7, pp. 1127-1131

2011

  1. Effectiveness of 7-valent pneumococcal conjugate vaccine in the prevention of invasive pneumococcal disease in children aged 7-59 months. A matched case-control study

    Vaccine, Vol. 29, Núm. 48, pp. 9020-9025